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Association of Decreased T-Cell-Mediated Natural Cytotoxicity 
and Interferon Production in Down’s Syndrome’ 
MADHAVAN P N. NAIR~ AND STANLEY A. SCHWARTZ’ 
Total peripheral blood lymphocytes (PBL) and isolated subpopulations from children 
with Down’s Syndrome (DS) and age-matched healthy controls were investigated for 
their t 1) natural killer (NK) and antibody-dependent cellular cytotoxic activities. (2) 
interleukin 2 (IL-2)-induced augmentation of NK activity. (3) lectin-dependent cellular 
cytotoxicity (LDCC). (4) ability of serum- and culture-derived soluble suppressor 
factor(s) to inhibit NK activity of normal lymphocytes, and 0 capacity to produce 
interferon (IFN) against tumor targets in vitro. T lymphocytes from DS patients dem- 
onstrated significantly decreased NK activity against K562 target cells compared to 
controls. DS lymphocytes also demonstrated a significant reduction in LDCC activity 
and IL-2-induced enhancement of NK activity. Furthermore. the ability of DS lympho- 
cytes to produce IFN in vitro against K562 target cells was also significantly lower than 
that for normal PBL. Although sera from DS patients showed a significantly greater 
inhibitory effect on the NK activity of allogeneic normal PBL than normal sera. culture 
supernates from DS lymphocytes demonstrated suppressive effects comparable to cul- 
ture supernates from normal PBL. These studies suggest an association between the 
decreased NK activity of T-cell subpopulations and lower IFN production by PBL from 
patients with DS. *c 19X4 Academic Pre*s. Inc 
INTRODUCTION 
An increased susceptibility to various infections and a high frequency of lym- 
phoproliferative malignancies has been observed in patients with trisomy-21 OI 
Down’s Syndrome (DS) (I-6). Evidence of immune defects in DS include con- 
flicting data on abnormal immunoglobulin levels (7, 8). deficiency of a cellular 
response (9, IO), thymic involution (11, 12), and lymphocyte depletion ( 13). 
Recent studies suggest that natural killer (NK) cell and antibody-dependent 
cellular cytotoxic (ADCC) activities are important because of their possible role 
in defense against tumors and virus infections and in the regulation of various 
lymphocyte reactions (14-18, 20). It has been shown that patients with cancer 
exhibit significantly lower NK and ADCC activities, thus potentially predisposing 
the host to progressive disease. The high susceptibility of DS patients to various 
viral infections and to leukemia is of particular significance since it provides an 
opportunity to study their NK and ADCC functions before the onset of clinically 
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apparent disease. The present report examines the NK and ADCC activities and 
lectin- and interleukin 2 (IL-2)-induced cytotoxicity of DS lymphocytes in com- 
parison with age-matched control lymphocytes from healthy donors. These 
studies demonstrate a significant defect in lectin- and IL-2-induced cytotoxicity 
and NK activity associated with purified T cells of DS patients. Our findings are 
consistent with previous reports of deficiencies of thymus-dependent immune 
functions in DS patients and may provide a cellular basis for the increased sus- 
ceptibility to various infections and high risk of malignancies observed in DS. 
MATERIALS AND METHODS 
Patients. Thirteen noninstitutionalized children of both sexes with cytogenet- 
ically proven trisomy-21, ranging from 2 to 60 months of age, with a median age 
of 25 months, and five healthy age-matched normal donors, ranging from 2 to 56 
months, with a median age of 24 months, were studied. Peripheral blood was 
drawn into a syringe containing 20 U/ml of heparin. Donors and their parents or 
guardians were apprised of the study and consents were obtained consistent with 
the policies of the University of Michigan and NIH. 
Isolation of peripheral blood lymphocytes (PBL). Mononuclear cells were iso- 
lated from heparinized venous blood using a modified method of Boyum (21). 
Blood was diluted with an equal volume of calcium- and magnesium-free Hanks’ 
balanced salt solution (HBSS) (GIBCO, Grand Island, NY) and centrifuged at 
400g for 30 min at 18°C over a cushion of Ficoll-Hypaque (Pharmacia Fine 
Chemicals, Piscataway, N.J.). The mononuclear cells band was harvested, washed 
three times with HBSS, and resuspended in RPM1 1640 medium, containing 25 
mM Hepes buffer supplemented with 5% heat-inactivated fetal calf serum (FCS; 
GIBCO), 80 p,g/ml gentamicin (Schering Corp., Kenilworth, NJ.), and 300 Fg of 
fresh glutamine per milliliter (complete medium). 
Depletion ofadherent cells. Mononuclear cells were depleted of adherent cells 
by the method of Ly and Mischell (22) as modified by. Berlinger et al. (23). Total 
mononuclear cells were suspended in RPM1 1640 with 10% FCS and passaged 
through a 7-ml column of Sephadex G-10 beads (Pharmacia) equilibrated in the 
same medium. After 45 min of incubation at 37”C, nonadherent cells (PBL) were 
washed through with one bed volume of warm (37°C) medium. The cell recovery 
was ~70% of the total input, and monocyte contamination as indicated by non- 
specific esterase staining was <2%. 
Preparation of T cells. T cells were prepared as described elsewhere (24). 
Briefly, 4 x lo6 PBL depleted of adherent cells were mixed with 0.25 ml of FCS 
absorbed with sheep red blood cells (SRBC) and 1 ml of 1% packed volume of 
neuraminidase-treated (25 U/ml in a 5% SRBC suspension) SRBC. The mixture 
was incubated at 37°C for 5 min and centrifuged at 200g for 5 min, followed by 
incubation at 4°C for 1 hr. The pellets were gently resuspended and T lymphocytes 
rosetted with SRBC were separated from non-T lymphocytes on a Ficoll-Hy- 
paque (Pharmacia) density gradient by centrifugation at 480g for 20 min at 20°C. 
SRBC attached to the isolated T lymphocytes (pellet) were lysed by hypotonic 
treatment with 1 ml of distilled water for 20 set, followed by 1 ml of double- 
strength minimal essential medium (MEM; GIBCO). T cells were washed three 
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times with RPM1 1640 and resuspended in complete medium and preincubated 
for 24 hr before use. 
Preparation of target cells. As targets, a highly sensitive human erythroleu- 
kemia cell line, K.562, was used in the NK assay. For the ADCC assay, antibod.y- 
coated SB cells derived from a patient with a B-cell leukemia served as targets. 
In vitro passaged 48-hr-old target cells were harvested and washed twice with 
complete medium. To 0.8-ml aliquots of complete medium containing 5 x lOh 
tumor cells, 200 $i of “Cr as sodium chromate (New England Nuclear, Boston. 
Mass.) was added. The cells were incubated at 37°C for I hr in a humidified 
atmosphere of 5% CO, in air with intermittent shaking. Following incubation, the 
cells were washed three times with complete medium and resuspended to a con- 
centration of 2 X lo5 cells/ml. 
Assay for NK activity. NK activity was determined in a direct “Cr-release 
assay as previously described ( 18. 20). A fixed number of viable effector cells in 
complete medium were added to triplicate cultures of 51Cr-labeled target cells 
in final volumes of 0.2 ml in V-bottom microtitration plates (Dynatech Labs. 
Alexandria, Va). After centrifugation at 40g for 2 min, they were incubated at 
37°C in a humidified atmosphere of 5% CO, in air for 4 hr. Percentage cytotoxicity 
was calculated as 
% cytotoxicity = 
experimental release - spontaneous release 
total release - spontaneous release 
x 100, 
where spontaneous release represents counts released from control wells con- 
taining only 2 x lo4 target cells, and total release represents counts obtained in 
an aliquot of 2 x lo4 lysed target cells. 
Assay for ADCC. The ADCC activity of effector cells was determined by the 
original method of Perlmann and Perlmann (25) as modified by Handwerger and 
Koren (26). Briefly, 50 ~1 of varying concentrations of effector cells was added 
to 50 p.1 of complete medium containing 5’Cr-labeled SB target cells and 100 ~1 
of a 2 x 10m4 dilution of rabbit anti-SB antisera previously found to yield maximal 
ADCC. Percentage cytotoxicity of ADCC activity was calculated as described 
above for NK activity with the following exceptions. Spontaneous release rep- 
resents counts released in control wells containing effector cells, labeled SB target 
cells, and medium instead of anti-SB antibodies, and total release represents 
counts obtained in an aliquot of 1 x lo4 “‘Cr-labeled SB target cells. 
Target binding assay. A target binding assay was used as described by Haliotis 
et al. (27). In brief, lymphocytes were washed twice and mixed with a fivefold 
excess of tumor cells, centrifuged at 150g for 5 min and incubated at 37°C for 5 
min. Following incubation, lymphocyte-target mixtures were transferred to ice. 
the pellets were gently resuspended, and the number of lymphocytes binding to 
tumor targets was determined using a hemocytometer. 
Znterleukin 2. Commercially available IL-2 (Electra-Nucleonics Labs. Inc.. 
Silver Spring, Md.) was diluted in RPM1 1640 and stored at - 70°C before use. 
The maximum NK augmenting dose (10% final concentration) as previously de- 
termined was used. 
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Treatment of effector cells with IL-2. PBL (2 x 106/ml) were washed and 
suspended in 1 ml of RPM1 1640 plus 5% FCS to which IL-2 (10% v/v), previously 
found to yield a maximum NK augmenting effect, was added. The cultures were 
incubated for 24 hr at 37°C in a humidified atmosphere of 5% CO? in air, washed 
twice, and resuspended in medium. Control cultures were treated identically with 
the exception that IL-2 was not added. Viability of treated lymphocytes was 
unaffected as assessed by trypan blue dye exclusion. Both treated and control 
cultures were assayed for NK activity. 
Lectin-dependent cell-mediated cytotoxicity assay (LDCC). The LDCC assay 
was carried out similarly to the NK assay. Briefly, target and effector cells were 
added to V-bottom microtitration plates, and various concentrations of phyto- 
hemagglutinin-P (Difco Laboratories, Detroit, Mich.), 0.5, 1, and 2.5 l&ml, were 
added to a final volume of 0.2 ml and incubated for 4 hr at 37°C in humidified 
5% CO, incubator. Percentage LDCC activity was calculated as described for the 
NK activity and was compared with cytotoxicity observed with control cultures 
containing effector and target cells. Percentage cytotoxicity was calculated as 
% cytotoxicity = 
experimental release - spontaneous release 
total release - spontaneous release 
x 100, 
where spontaneous release represents counts released from control wells con- 
taining 2 x IO4 target cells plus lectin, and total release represents counts ob- 
tained from 2 x lo4 lysed target cells. 
Preparation of soluble suppressor factors (SSF). SSF were prepared as pre- 
viously described (19, 20). Briefly mononuclear leukocytes from either normal 
donors or DS patients after being washed three times with normal saline were 
resuspended in RPM1 1640 medium containing only gentamicin and glutamine. 
Suspensions of 5 x lo6 cells/ml were incubated at 37°C in a humidified atmo- 
sphere of 5% CO, in air for 5 days. After incubation, supernates were separated 
by centrifugation at SOOg for 30 min and stored at -20°C. Control supernates 
prepared in the absence of cells were treated similarly and termed mock SSF. 
Incubation of effector cells with SSF. Duplicate sets of cultures containing 2 
x lo6 PBL in 0.8 ml of RPM1 1640 plus glutamine, gentamicin, and 5% FCS were 
added to a tube containing 200 ~1 of SSF or mock SSF (20% v/v) and incubated 
in a humidified environment of 5% CO, in air at 37°C for 72 hr. Cells were then 
washed twice and resuspended in complete medium. Cell viability in SSF-treated 
cultures was comparable with that of mock SSF-treated cultures as determined 
by trypan blue dye exclusion and was found to be 80 to 90%. Treated and control 
cultures were tested for their ability to mediate NK activity. 
Interferon (ZF’N) assay. Lymphocytes were cultured alone or with K562 target 
cells at a ratio of 100: 1 for 18 hr at 37°C in 5% CO, in air, after which they were 
centrifuged and the supernates were collected for IFN assay. Supernates were 
quantitated for IFN using the modified calorimetric assay of Borden and Leon- 
hardt (28). Briefly, 96-well flat-bottom microtitration plates (Costar, Cambridge, 
Mass.), were seeded with human epithelial cells (WISH) at a concentration of 3 
x lo4 cells/well in 0.1 ml of medium and incubated for 18 hr. Serial dilutions of 
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supernates (1: 10, I :40, I : 160, and I:3201 were added in 0. I ml and incubated again 
for 8 hr. The cells were then infected with vesicular stomatitis virus (VSV). 200 
plaque forming units/well, for 24 hr. After development of cytopathic effect, cul- 
tures were washed with PBS and overlaid with 0.2 ml of 0.015% neutral red in 
saline and incubated for 2 hr at 37°C. The monolayers were washed and the 
cellular dye was eluted with a 1:l solution of absolute ethanol:0.2 M NaH,PO,. 
As a control, an IFN preparation standardized against NIH reference G023-901- 
527 of known concentrations ranging from 2 to 300 U/ml was included in the 
assay. This assay is highly reproducible and can detect as little as 4 U/ml of fFN. 
RESULTS 
NK und ADCC Activities oj’Lymphocgtes jiom I>S Putirnts 
NK and ADCC effector cells have been shown to be important in immune 
surveillance against neoplasia. Since DS patients show increased susceptibility 
to leukemia, various subpopulations of mononuclear cells from these patients 
were tested for their NK and ADCC activities against target cells at different 
effector to target (E:T) ratios. Data presented in Table 1 demonstrate that. itI- 
though total unfractionated PBL from DS patients consistently show decreased 
NK and ADCC activities at different E:T cell ratios. these values were not sta- 
tistically different from those for normal PBL. 
As previous studies have suggested defects in cell-mediated immunity among 
DS patients, we specifically examined the NK activity of purified T lymphocytes 
from patients with trisomy-21 and compared this with T cells isolated from age- 
matched normal donors. Table 2 demonstrates that T lymphocytes from DS pa-. 
tients are significantly decreased in NK activity (19%) compared to the higher 
cytotoxicity (41%) displayed by normal T lymphocytes (P < 0.025). Non-T cells 
from normal and DS donors, however, showed higher and comparable NK ac- 
TABLE I 
NK AND ADCC A~IIVITIES ot NORMAL ANI) DOWN’~ SYNDKUM~ LYMPHOC Y IW 
Effector:target cell ratio 
Target Effector source 50: I 25:i 10: I C:l 
V Cytotoxicil) 
K562’ Normals 44.1 i 13.7 31.8 7 x.4 17.4 + 5.x 8 Y z! 7 .3 
DS 25.7 i- 15.5 26.0 -+ 15.3 14.5 t 10.0 4.9 z 5.9 
SB” Normals 41.7 t 14.7 33.Y  ̂ 16.X 23.0 t I I.8 13.3 7 4.3 
DS 23.6 i 16.2 19.2 2 Il.6 13.3 2 6.2 Y.J 7 3.‘) 
” Effector cells were depleted of phagocytic cells and mixed with target ceils as detailed under 
Materials and Methods at varying E:T cell ratios in a 4-hr “O-release assay. The results are the 
means 2 SD performed in triplicate of 13 separate patients and 5 age-matched normal donors 
b Percentage cytotoxicity was calculated as under Materials and Methods. 
( Erythroleukemia cell line used as targets in NK assay. 
d B-Leukemia cell line sensitized with anti-SB antibody used as targets in ADCC assay. Difference\ 
in values between the normals and DS patients were not statistically significant at any E:T cell ratio 
in both NK and ADCC assays using single-tailed Student’? I test. 
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TABLE 2 





T cells’ Non-T cells’ 
41.2 2 6.4’ 58.2 e 5.1 
(P < 0.025) (P < 0.1) 
19.5 k 4.2 54.5 2 5.6 
U T cells were isolated by rosetting with neuraminidase-treated SRBC as described under Materials 
and Methods. 
b % Cytotoxicity was calculated as under Materials and Methods. 
( T cells contained >92% E-rosette-positive cells, ~0.05% fluorescent, polyvalent surface Ig- 
bearing cells, and <l% nonspecific esterase-positive and latex-ingesting phagocytic cells. 
d Non-T cells are lymphocytes separated from rosetted T cells on a Ficoll-Hypaque gradient. 
Non-T cells contained ~2% E-rosette-positive cells and <OS% nonspecific esterase-positive and 
latex-ingesting cells. 
p Results are means 2 SD of 3 experiments performed at 50: 1 E:T cell ratio. Statistical values were 
determined by single-tailed Student’s t test. 
tivity, 58 and 54%, respectively. Examination of the target binding ability of mono- 
nuclear cells showed that lymphocytes from DS patients exhibit a normal range 
of target binding capacity against K562 targets compared to that of control lym- 
phocytes (Table 3). 
Effect of IL-2 on NK Activity of DS Lymphocytes 
We investigated whether IL-2 could augment the cytotoxicity of DS lympho- 
cytes to the same level shown by normal lymphocytes. Data presented in Table 
4 demonstrate that normal PBL precultured with IL-2 showed 61% cytotoxicity 
compared to 20% cytotoxicity displayed by untreated cultures. DS lymphocytes 
precultured with IL-2 demonstrated an increased cytotoxicity (38%) compared to 
that of untreated lymphocytes (21%). The percentage enhancement of IL-2-in- 
duced cytotoxicity of DS lymphocytes was significantly lower (82%) compared 
with that of normal lymphocytes (197%) (P < 0.0025). This indicates that, al- 
though the cytotoxicity of DS lymphocytes could be enhanced considerably by 
IL-2, the cytotoxic potential was not augmented to the levels shown by normal 
lymphocytes. 
Effect of Lectin on Cellular Cytotoxicity (LDCC) of DS Lymphocytes 
Since DS lymphocytes demonstrated reduced IL-2-induced cytotoxic potential, 
we examined whether their cytotoxicity could be activated with lectin to the levels 
shown by normal lymphocytes. Data presented in Table 5 demonstrate that normal 
PBL at an E:T ratio of 50: 1 produced 40, 46, and 45% LDCC activity against SB 
targets at 0.5, 1, and 2.5 pg/ml of PHA, respectively, compared to 7% cytotoxicity 
observed in the absence of PHA. PBL from DS patients showed 5% cytotoxicity 
without PHA: cytotoxicity was considerably enhanced to 13, 14, and 15% by 
PHA at 0.5, 1, and 2.5 pg/ml concentrations, respectively. Although PHA could 
significantly enhance the cytotoxicity of DS lymphocytes, activity was not en- 
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TABLE 3 




Expt Effector source (V) 
I Normal 17 
DS (LC) II 
2 Normal I5 
DS (PR) I3 
3 Normal I 3 
DS (HC) 13 
’ Effector and target cells were mixed at an E:T ratio of 5:l and incubated at 37°C for 30 min. 
followed by 0°C for 1 hr. Aliquots were examined in a hemocytometer and a positive target-binding 
cell was scored for each lymphocyte binding two or more target cells. 
b The human erythroleukemia cell line, K562. was used as target in binding study. 
hanced to the levels shown by normal PBL. For example, normal PBL demon- 
strated 464, 550, and 538% enhancement of their residual cytotoxicity compared 
to significantly reduced enhancement of 157 (P < 0.051, 189 (P < 0.005), and 
214% (P < 0.0025) shown by DS lymphocytes at 0.5, I, and 2.5 pg/ml concen- 
trations of PHA, respectively. 
Interferon Production by DS Lymphocytes In Vitro 
Since earlier studies (29) demonstrated a reduced augmentation of IFN-induced 
NK activity of DS lymphocytes compared to normal lymphocytes, we examined 
the ability of DS lymphocytes to produce IFN against K562 target cells in LGtro. 
Data presented in Table 6 demonstrate that DS lymphocytes produced signifi- 
cantly lower levels of IFN (1443 + 223 U/ml) compared to those of normal 
lymphocytes (2675 ir 120 U/ml) (P < 0.005). 
TABLE 4 
EFFECTOF INTERLEUKIN 2 ON NK ACTIVITY OF DS LYMPHOCYTE? 
% Cytotoxicity’ 
Effector Medium 
source control + IL-’ % Enhancement’ 
,~. 
Normals 20.6 k 3.2” 61.2 z 5.8 197.? 
(P i .0025) 
DS 20.9 ? 2.3 38.0 ~tl 2.3 81.8 
--_______ -- 
a Lymphocytes (2 x 106) depleted of adherent cells were cultured alone or with IL-? (IO% v/v) for 
24 hr, washed, and tested for their NK activity against K.562 target cells at an E:T cell ratio of 20: 1. 
’ % Cytotoxicity was calculated as under Materials and Methods. 
’ Enhancement was calculated on the basis of cytotoxicity obtained when lymphocytes were pre- 
cultured in medium alone. 
d Values represent mean % cytotoxicity ? SD of 4 separate experiments done in triplicate. Stat& 
tical significance was determined using a single-tailed Student’s I test. 
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TABLE 5 
EFFECT OF LECTI~ ON CELLULAR CYTOTOXICITY OF DS LYMPHOCYTES 
Lymphocyte 
sourceb 0 
PHA concentration (kg/ml) 




7.1 k 1.4d 40.1 i 8.9 (464.7) 46.2 4 5.2 (550.7) 45.3 2 5.4 (538.0) 
P < 0.05 P < 0.005 P < 0.0025 
4.9 2 2.4 12.6 2 5.2 (157.1) 14.2 2 3.1 (189.1) 15.4 t 2.1 (214.2) 
’ The lectin-dependent cellular cytotoxicity assay was carried out similarly to the NK assay except 
the NK-resistant SB cell line was used as target as described under Materials and Methods. 
’ Lymphocytes depleted of adherent cells. 
(’ % Cytotoxicity was calculated as described under Materials and Methods. 
d Values represent mean % cytotoxicity 2 SD of 4 separate experiments employing 4 DS patients 
and 4 age-matched controls. Experiments were performed in triplicate at a 50:1 E:T cell ratio. Sta- 
tistical values were determined by single-tailed Student’s r test. Values in parentheses are % enhance- 
ment of cytotoxicity. 
Effect of Soluble Factors on NK Activity of Normal Lymphocytes 
We examined the effect of SSF on the NK activity of fresh allogeneic cells 
derived by preculturing DS lymphocytes. The results show (Table 7) that normal 
lymphocytes precultured with SSF prepared from healthy allogeneic donors dem- 
onstrated 21.5% cytotoxicity compared to 37% cytotoxicity shown by mock SSF 
(42.2% suppression). Lymphocytes precultured with SSF prepared from DS lym- 
phocytes also demonstrated a significant decrease in their NK activity (22.7%) 
compared to the cytotoxicity (37.2%) obtained when lymphocytes precultured 
with mock SSF (38.9% suppression). This suggests that the immunoregulatory 
functions of suppressor cells and their soluble products in DS patients are com- 
parable to those of normal healthy subjects. 
TABLE 6 







Normal lymphocytes + 
target cells (K562) 
DS lymphocytes + 




2675 2 120 
(P < 0.005) 
1443 k 223 
” Supemates were obtained from cell cultures incubated for 18 hr at 37°C in a 5% CO, atmosphere. 
Mixtures of effector and target cells were set up at 1OO:l E:T cell ratios (previously determined to 
yield maximum IFN). IFN in the supemates was assayed as detailed under Materials and Methods. 
Results are means 2 SD of 3 experiments. Statistical values were determined by single-tailed Stu- 
dent’s t test. 
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TABLE 7 






.-____-. --.- -- 
Mock SSF’ 37.2 f  3.1 f  -- 
Normal lymphocytes 31.5 i- 7.1 42.2 
DS lymphocytes 22.7 i 9.0 3x.9 
” Allogeneic normal adult lymphocytes (- 7 x lOhI depleted of adherent cells were cultured in com- 
plete medium supplemented with a 20% (v/v) concentration of either a medium control or supernates 
from precultured DS lymphocytes or age-matched normal PBL. After 72 hr the cells were examined 
for NK activity against K562 cells. 
h Supernates of lymphocytes cultured for 4 days at 37°C in 5% CO, in air, was used as a source of 
soluble suppressor factor. 
( Cytotoxicity was calculated as under Materials and Methods. 
d Suppression of cytotoxicity was calculated as under Materials and Methods. 
r Medium incubated in absence of lymphocytes. 
f  Values represent mean % cytotoxicity t SD of 4 separate experiments done in triplicate at a 50: I 
E:T cell ratio. 
Sera from DS Patierlts Inhibit NK Activities of Normal Lymphocytes 
Studies by ourselves (30) as well as others (31, 32). demonstrated that normal 
serum contains inhibitory factors directed against NK and ADCC functions of 
normal autologous and allogeneic PBL, and that these inhibitory factors are sig- 
nificantly higher in sera from a variety of cancer patients. We investigated the 
ability of DS serum to inhibit NK activity of allogeneic PBL from normal donors. 
The data presented in Table 8 demonstrate that four of five samples of DS serum 
significantly inhibited the NK activity of normal PBL compared to that of normal 
serum. 
DISCUSSION 
Because of the increased predisposition of patients with DS to infections and 
leukemia, analysis of their immune status is an important clinical parameter. 
Deficiencies of both humoral immunity and cell-mediated immunity have been 
implicated in the syndrome, although the underlying cellular mechanisms remain 
unclear. Lopez et al. (33) demonstrated a defect in specific antibody synthesis to 
bacteriophage in Go in DS patients. A high incidence of autoantibodies (34, 35) 
and increased susceptibility to hepatitis viruses (36) have also been reported. 
Burgio and Nespoli (37) showed that both thymus-dependent and independent 
functions were impaired in DS patients with a characteristic chronologic se- 
quence. Nurmi et al. (38) observed a lower antibody response to pneumococcal 
vaccine in DS patients. Segar et al. (39) and Serra et al. (40) reported that the 
transformation responses of trisomic lymphocytes to PHA decreased with age. 
Thymic abnormalities (11, 12) and deficiencies in the number and functions of T 
lymphocytes (37) have also been demonstrated. Nurmi et al. (29) recently ob- 
served normal NK and ADCC reactions in unseparated lymphocyte populations 
in adult DS patients compared to lymphocytes from normal donors. We have 
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made a similar observation in children with DS as reported herein. However, 
when T lymphocytes from DS patients are separated from other mononuclear 
subpopulations and specifically examined for NK activity they manifest signifi- 
cant deficiencies when compared to T cells from normal donors. Thus this subtle 
defect could be overlooked if only total lymphocytes are examined and only 
becomes manifest upon isolation of T cells. Previous investigations suggest that 
T cells are involved in NK and ADCC mechanisms (41, 42) as well as in the 
regulation of other immunologic reactions (42-44). It has also been proposed that 
NK cells have characteristics of pre-T cells (45, 46). The decreased NK activity 
of T cells from DS patients is unlikely due to either increased or decreased 
sensitivity of DS T lymphocytes to rosetting and hypotonic treatment compared 
to normal T cells. Rosetting and hypotonic shock is a well-established method 
for obtaining viable and functionally active T cells (47). When T cells from DS 
patients and controls were isolated by this technique, both populations were 
equally viable (~97%) as tested by trypan blue dye exclusion and contained < 1% 
nonspecific esterase-positive cells. Furthermore, T-cell populations were prein- 
cubated for 24 hr in complete medium at 37°C in 5% CO, in air to allow shedding 
of bound RBC fragments, turn over of newly synthesized membrane receptors, 
and equilibration of functional activities. When experiments are set up, equal 
numbers and concentration of viable cells from both DS patients and controls 
were run simultaneously. The decreased NK activity of T lymphocytes from DS 
patients as observed in the present study may represent yet another example of 
a functional deficiency of T-cell maturation or differentiation in these patients 
which may lead to increased susceptibility to various infections and leukemia. 
Sera from cancer patients appear to contain suppressor factors capable of in- 
hibiting NK and ADCC reactions (30-32). Analysis of serum factors that can 
inhibit NK activity may thus be relevant to host resistance to certain infections 
and tumor growth. In the present investigation, sera from DS patients showed 
significant inhibitory effects on the NK functions of normal PBL (Table 8). This 
suggests that the immunodeficiency observed in DS may be correlated with the 
development of SSF. The ability of DS serum to suppress the NK activity of 
normal lymphocytes in vitro may reflect similar inhibitory effects on NK effector 
cells in Go. Therefore increases in SSF activity in the sera of DS patients may 
predispose them to various infections and possibly to malignancy. 
NK cells appear to have some selectivity since certain targets are very sus- 
ceptible whereas others are resistant. This may be due to differences in the an- 
tigenic structures present on target cells or the receptor sites on NK cells or both. 
It has been demonstrated that lymphocyte cytotoxicity can be activated by lectin 
(PHA). The exact function of lectin activation is not presently understood, but it 
has been suggested that it may act directly on cytotoxic cells by rearranging 
cryptic receptors for recognition sites on target cells, providing sufficient signals 
to trigger subsequent lytic events (48, 49). In the present report the cytotoxicity 
of DS lymphocytes could be considerably enhanced by PHA, even though cy- 
totoxicity could not be stimulated to the levels shown by normal PBL (Table 5). 
suggesting a defect in the LDCC activity of DS lymphocytes. 
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TABLE 8 
SUPPRESSION OF NK ACTIVITIES OF NORMAL AI.I.OGENEIC LVMPHWYTES BY SERUM FROM DS 
PATENTS AND NORMAI. DONO& 
Concentration of serum (viv, 
Serum source 5% 
--..-““;-~ ._--. --...2: -- 
(I Cytotoxicity” 
Normal 1 40.0 35.0 20.1 
Normal 2 34.3 31.1 29.6 
Normal 3 42.2 38.4 30.2 
Normal 4 33.0 3 1 .o 29.2 
DSl 40.4 ( - 7.2’) 22.Y l32.?J Il.08 (67.3) 
DS 2 18.0 (51.7) 15.8 (53.2) 10.3 (65.8) 
DS 3 21.4 (42.6) 20.3 (39.9) 15.5 (48.6) 
DS 4 25.2 (32.4) 24.1 (28.6) 20.4 (32.4) 
DS 5 33.4 (10.4) N D” 31.7 (--4.9) 
n Allogeneic normal adult PBL depleted of adherent cells were precultured separately with either 
DS serum or age-matched normal serum (heat inactivated for 30 min at 56°C) at a 5, 10, and 20% 
final concentration for 24 hr in a 5% CO? incubator. After washing, viable cells were tested for their 
NK activity at a 50: I E:T cell ratio as described under Materials and Methods. The erythroleukemia 
cell line, K.562. was used as targets for NK activity. 
h Percentage cytotoxicity was calculated as under Materials and Methods. 
c Numbers in parentheses are % suppression of NK activity by individual serum samples. which 
was calculated on the basis of mean % cytotoxicity shown by age-matched normal sera used as 
controls. The mean % cytotoxicity t SD were 37.3 2 4.4, 33.8 i- 3.5. and 30.2 c 1.2. at 5. 10. and 
20% final concentrations of normal serum, respectively. A minus sign ( - ) indicates enhancement. 
d Not done. 
The gene responsible for the species-specific response to IFN has been mapped 
on chromosome 21 in man and has been designated as the IFN receptor gene (SO, 
51). IFN and IL-2 have been used as stimulators of NK cell activity. The sus- 
ceptibility of target cells to NK lysis may be dependent, in part, upon the ability 
of effector lymphocytes to produce IFN against the target cells (52, 53). Nurmi 
et al. (29) recently observed that NK activity of DS lymphocytes against K562 
target cells was not augmented by IFN to the same levels shown by normal 
lymphocytes. The present investigation demonstrates that a significant defect is 
associated with DS lymphocytes in the production of IFN in ~ifro against K562 
target cells (Table 6). Although total PBL in DS patients demonstrate NK activity 
comparable to that in normal donors, a significantly decreased ability of DS lym- 
phocytes to produce IFN in response to exogenous agents, such as viruses, bac- 
teria, or neoplastic cells, may eventually result in a diminished host immune 
surveillance against infections and malignancy. The production of IFN against 
K.562 targets and various IFN inducers in ~itvo by separated T cells from DS 
patients as well as the stimulatory effect of IFN on the suppressed NK activity 
of T lymphocytes remains to be studied. In earlier studies IL-2 was shown to be 
involved in the production of IFN (54, 55). The present investigation demon- 
strates a defect in DS lymphocytes’ response to IL-2, since IL-2-induced cyto- 
toxicity of DS lymphocytes was not augmented to the levels shown by normal 
lymphocytes (Table 4). Further we examined whether immunologic deficiencies 
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observed in DS patients may be due, in part, to active suppressor cell mecha- 
nisms, lack of target binding ability, or increased ability of DS lymphocytes to 
produce culture-induced SSF. It was shown that no inhibition of NK or ADCC 
activities of normal lymphocytes by DS lymphocyte subpopulations was observed 
in coculture experiments (data not presented), trisomic lymphocytes exhibited a 
normal range of target binding capacity (Table 3), and the inhibitory effect of 
culture-induced SSF from DS lymphocytes was also comparable with that of 
normal lymphocytes. These findings suggest that the deficiencies of NK activity 
associated with the T-lymphocyte subpopulation, IL-2 and LDCC, and reduced 
IFN production observed in DS patients are probably due to intrinsic defects in 
the effector cells rather than due to immunoregulatory dysfunctions. These im- 
munopathologic mechanisms may thus predispose DS patients to repeated infec- 
tions and possibly to eventual leukemia. 
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